EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access

Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle–Income Country Setting

Kirati Kengkla iD, Surakit Nathisuwan iD, Warunsuda Sripakdee, Pirun Saelue iD, Kwanruethai Sengnoo, Aumkhae Sookprasert, Suphat Subongkot iD

JCO Global Oncology · 2024

DOI: 10.1200/go.23.00353 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Kirati Kengkla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand. Hauptthemen laut MEDLINE: Neoplasms, Thrombosis, Venous Thromboembolism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate anticoagulant trends and clinical outcomes in the management of cancer-associated thrombosis (CAT) within Thailand, an upper-middle–income country (UMIC). METHODS This multicenter retrospective cohort study included adult patients with cancer diagnosed with venous thromboembolism (VTE) hospitalized in Thailand from 2017 to 2021. Anticoagulants were classified as low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOACs), and warfarin. Prescription trends were assessed, and patients were followed for 1 year, or until 2022 to evaluate outcomes. The primary effectiveness outcome was recurrent VTE, whereas the primary safety outcome was major bleeding. Secondary outcomes included net clinical benefit and all-cause mortality. Treatment effects were examined using inverse probability of treatment weighting (IPTW) Cox proportional hazards models. RESULTS Among 1,611 patients (61.3% female; mean age, 58.8 years; standard deviation, 13.1 years), 86% received LMWH, 10% warfarin, and 4% DOACs. In the study cohort, LMWH prescriptions remained consistent, warfarin use declined, and DOAC prescriptions notably increased. In IPTW analysis, DOACs showed comparable rates of VTE recurrence (weighted hazard ratio [HR], 0.77 [95% CI, 0.22 to 2.70]; P = .679) and major bleeding (weighted HR, 0.62 [95% CI, 0.15 to 2.55]; P = .506) with LMWH. Warfarin had a higher risk of major bleeding (weighted HR, 2.74 [95% CI, 1.12 to 6.72]; P = .028) but a similar rate of VTE recurrence (weighted HR, 1.46 [95% CI, 0.75 to 2.84]; P = .271) compared with LMWH. Secondary outcomes were consistent across groups. CONCLUSION LMWH remains the primary treatment for CAT, in line with current guidelines. The study highlights the challenges faced in these settings with the continuous use of warfarin. The comparable efficacy and safety of DOACs with LMWH suggest a potential shift in CAT management within UMICs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsThrombosisVenous ThromboembolismAdultFemaleHumansMaleMiddle AgedAnticoagulantsHemorrhageHeparin, Low-Molecular-WeightRetrospective StudiesThailandWarfarinAged

Substanzen

AnticoagulantsHeparin, Low-Molecular-WeightWarfarin

Autor:innen und Institutionen

  • Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand.
  • The College of Pharmacotherapy of Thailand, Nonthaburi, Thailand.
  • Division of Pharmacy Practice, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.
  • Clinical Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
  • Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand.
  • Hematology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.

ORCID-Profile: Kirati Kengkla, Surakit Nathisuwan, Pirun Saelue, Suphat Subongkot

Zitieren

APA

Kengkla, K., Nathisuwan, S., Sripakdee, W., Saelue, P., Sengnoo, K., Sookprasert, A., & Subongkot, S. (2024). Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle–Income Country Setting. JCO Global Oncology. https://doi.org/10.1200/go.23.00353

Vancouver

Kengkla K, Nathisuwan S, Sripakdee W, Saelue P, Sengnoo K, Sookprasert A, et al. Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle–Income Country Setting. JCO Global Oncology. 2024. doi:10.1200/go.23.00353

BibTeX
@article{Kengkla2024,
  author = {Kengkla, Kirati and Nathisuwan, Surakit and Sripakdee, Warunsuda and Saelue, Pirun and Sengnoo, Kwanruethai and Sookprasert, Aumkhae and Subongkot, Suphat},
  title = {Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle–Income Country Setting},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.23.00353}
}
Kostenlos starten →